Kefadol
C19H18N6O6S2 — CID 5284527
View drug profile → cefamandole nafateData last refreshed: (MolForge compound catalog, from PubChem)
About Kefadol
Kefadol (PubChem CID 5284527) has the molecular formula C19H18N6O6S2 and a molecular weight of 490.52 g/mol. Its IUPAC name is (6R,7R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
Molecular Properties
| Compound Name | Kefadol |
|---|---|
| PubChem CID | 5284527 |
| Molecular Formula | C19H18N6O6S2 |
| Molecular Weight | 490.52 g/mol |
| Exact Mass | 490.07 |
| IUPAC Name | (6R,7R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| SMILES | Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1 |
| InChI | InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1 |
| InChIKey | RRJHESVQVSRQEX-SUYBPPKGSA-N |
| XLogP | -0.04 |
| TPSA | 156.61 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 490.52 |
| LogP ≤ 5 | -0.04 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 11 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'aldehyde', 'substructure': 'N/A'} |
|---|
Related Compounds
Frequently Asked Questions
Browse: Molecules: K · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 5284527 — identifiers, structure, computed properties (public domain)
- DrugCentral drug card 528 — approved-drug record (CC BY-SA 4.0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.